---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000157"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:21:21.716829+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# John Quisel appointed to Gossamer Bio Board; brings PAH expertise from Acceleron/Merck

## Summary
- Appointed Class III director, term expiring at 2024 annual meeting; joins Audit Committee.
- Received option to purchase 230,000 shares vesting monthly over three years, plus $40,000 board retainer and $7,500 audit retainer annually.
- Currently President & CEO of Disc Medicine; previously at Acceleron Pharma leading re-acquisition of sotatercept rights for PAH from Bristol-Myers Squibb.
- Led initiative that culminated in Merck's $11B acquisition of Acceleron in 2021, highlighting deep PAH corporate development experience.

## SEC filing metadata
- accession: 0001728117-23-000157
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/0001728117-23-000157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/goss-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000157
- JSON: https://secwatch.observer/filing/0001728117-23-000157.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000157.txt

## Key facts
- Executive change
  John Quisel was appointed as Class III Director at Gossamer Bio, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: the Board appointed John Quisel, J.D., Ph.D. to serve as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000157/0001728117-23-000157-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.